Beyond Detectable Minimal Residual Disease in Chronic Lymphocytic Leukemia

Seminars in Oncology

Volumn 33, Issue SUPPL. 5, 2006, Pages 23-28

  Hillmen, Peter ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CD23 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; MONOCLONAL ANTIBODY; PROTEIN KINASE ZAP 70; RITUXIMAB;

ARTICLE; BONE MARROW; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; FLOW CYTOMETRY; GENE MUTATION; HUMAN; LYMPHOCYTE COUNT; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SEX DIFFERENCE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; NEOPLASM, RESIDUAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646584485     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.01.026     Document Type: Article

References (36)

1. Oscier D., Fegan C., Hillmen P., et al. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 125 (2004) 294-317
2. Keating M.J., O'Brien S., Lerner S., et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92 (1998) 1165-1171
3. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1750-1757
4. Dighiero G., and Binet J.-L. When and how to treat chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1799-1801
5. Dighiero G., Maloum K., Desablens B., et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 338 (1998) 1506-1514
6. Shanafelt T.D., Geyer S.M., and Kay N.E. Prognosis at diagnosis. integrating molecular biologic insights into clinical practice for patients with CLL. Blood 103 (2004) 1202-1210
7. Rai K.R., Sawitsky A., Cronkite E.P., et al. Clinical staging of chronic lymphocytic leukemia. Blood 46 (1975) 219-234
8. Binet J.L., Auquier A., Dighiero G., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48 (1981) 198-206
9. Hamblin T.J., Davis Z., Gardiner A., et al. Unmutated Ig Vh genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94 (1999) 1848-1854
10. Damle R.N., Ghiotto F., Valetto A., et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated antigen-experienced B lymphocytes. Blood 99 (2002) 4087-4093
11. Hamblin T. Is chronic lymphocytic leukemia one disease?. Haematologica 87 (2002) 1233-1235
12. Wiestner A., Rosendwald A., Barry T.S., et al. ZAP-70 expression identified a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. Blood 101 (2003) 4944-4951
13. Rassenti L.Z., Huynh L., Toy T.L., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351 (2004) 893-901
14. Crespo M., Bosch F., Villamor N., et al. ZAP-70 expression as a surrogate for immunoglobulin variable region mutations in chronic lymphocytic leukemia. N Engl J Med 348 (2003) 1764-1775
15. Stilgenbauer S. Chronic lymphocytic leukaemia with high-risk genetics. Disease progression and resistance to therapy. Leuk Lymphoma 46 suppl 1 (2005) S6
16. Volkheimer A.D., Levesque M.C., Beasley B.E., et al. Prognostic features in chronic lymphocytic leukaemia-Lack of utility of Zap-70 as a prognostic marker. Leuk Lymphoma 46 suppl 1 (2005) 20 (abstr S44)
17. Döhner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1910-1916
18. Sturm I., Bosanquet A.G., Hermann S., et al. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 10 (2003) 477-484
19. Döhner H., Fischer K., Bentz M., et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85 (1995) 1580-1589
20. Byrd J.C., Smith L., Hackbarth M.L., et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 63 (2003) 36-38
21. el Rouby S., Thomas A., Costin D., et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82 (1993) 3452-3459
22. Lozanski G., Heerema N.A., Flinn I.W., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103 (2004) 3272-3281
23. Stilgenbauer S., Winkler D., Krober A., et al. Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL. Interim analysis of the CLL2h study of the German CLL Study Group (GCLLSG). Blood 104 (2004) 235 (abstr 478)
24. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia. Revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
25. Rawstron A.C., Kennedy B., Evans P.A.S., et al. Quantitation of minimal residual disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98 (2001) 29-35
26. Keating M.J., O'Brien S., Kontoyiannis D., et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 43 (2002) 1755-1762
27. Moreton P., Kennedy B., Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23 (2005) 2971-2979
28. Bosch F., Ferrer A., Lopez-Guillermo A., et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 119 (2002) 976-984
29. Campath Product Insert (2002), Berlex, Inc, Seattle, WA
30. Rituxan Product Insert. San Diego, CA, IDEC Pharmaceutical Corporation and South San Francisco, CA, Genentech Inc, 2004
31. Montillo M., Tedschi A., Rossi V., et al. Consolidation with alemtuzumab after a response to fludarabine in patients with CLL. confirmation of the efficacy to purge residual disease. Leuk Lymphoma 46 suppl 1 (2005) 107 (abstr S93)
32. O'Brien S.M., Gribben J.G., Thomas D.A., et al. Alemtuzumab for minimal residual disease in CLL. Blood 102 (2003) 109a (abstr 371)
33. Wendtner C.-M., Ritgen M., Schweighofer C.D., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL study group. Leukemia 18 (2004) 1093-1101
34. Keating M., O'Brien S., Albitar M., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 4079-4088
35. Wierda W., O'Brien S., Wen S., et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 4070-4078
36. Elter T., Borchmann P., Schulz H., et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Results of a phase II trial. J Clin Oncol 23 (2005) 7024-7031